Fever Management of Critically Ill Patients with COVID-19 Infection: Less is More?


avatar Ata Mahmoodpoor ORCID 1 , avatar Sarvin Sanaie ORCID 2 , avatar Mohammad-Salar Hosseini ORCID 3 , *

Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

how to cite: Mahmoodpoor A, Sanaie S, Hosseini M. Fever Management of Critically Ill Patients with COVID-19 Infection: Less is More?. Int J Infect. 2021;8(1):e107422. https://doi.org/10.5812/iji.107422.

Dear Editor,

Although physicians usually intervene to treat fever in critically ill patients, the relationship between body dysthermia (both hypothermia or hyperthermia) and these patients' outcomes are not well understood (1, 2). Fever is practically the most prevalent clinical feature at the onset of an illness during the hospitalization of patients with SARS-CoV-2 infection (3). Some studies report that fever management in critically-ill patients can increase infection risk without a decrease in mortality (4). For example, a recent meta-analysis on forty-two studies has suggested that the mortality rate is lower in septic patients with fever (5). Another study described no significant difference in critically ill patients' mortality rates between the patients with more-active fever management and less-active fever management (6). Compatibly, the results of a recently published meta-analysis show that the use of antipyretic drugs and external cooling is associated with higher risk mortality in septic ICU patients who require mechanical ventilation (7).

It is difficult to determine whether the excellent outcome of the critically-ill hyperthermic patients is due to their appropriate ability to respond to the acute phase or the fever response itself. On the other hand, an ideal target temperature range optimal for organ function is unclear (8). Moreover, it is still uncertain when and how to attempt to reduce the temperature in a patient with elevated body temperature (9).

Humans are not adapted to critical illnesses, and in the absence of contemporary medicine and benefits of intensive care, most critically-ill, febrile, and infected patients with infection and fever would undoubtedly die. Each physician should attentively consider the balance between the potential benefits of reducing metabolic rate and the possible risks of a harmful effect on the host’s defense mechanisms with fever control.

The definite impact of the antipyretics’ fever-lowering effect on critically-ill patients with COVID-19 infection is presently unknown. Hence, the general approach to the systematic suppression of fever in these patients is not recommended, and antipyretics should be administered based on each patient’s condition. Although a fever response, which is in the physiological range with compensating changes and settled vital signs, is preferred not to be treated, the deterioration in vital signs (such as respiratory rate and heart rate), or the patients’ general condition and interventions to treat hyperthermia should be implemented. Precise, safe, and efficient temperature control is now doable; however, the most crucial point is to avoid hypothermia in these patients and maintain normothermia through pharmacologic or non-pharmacologic interventions.


  • 1.

    Niven DJ, Shahpori R, Stelfox HT, Laupland KB. Management of febrile critically ill adults: a retrospective assessment of regional practice. Ther Hypothermia Temp Manag. 2011;1(2):99-104. [PubMed ID: 24717000]. https://doi.org/10.1089/ther.2011.0002.

  • 2.

    Gulati S, Maheshwari A. Infectious Diseases in the Intensive Care Unit. Management of Viral Infections in ICU. Springer; 2020. p. 211-27. https://doi.org/10.1007/978-981-15-4039-4_15.

  • 3.

    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. [PubMed ID: 32031570]. [PubMed Central ID: PMC7042881]. https://doi.org/10.1001/jama.2020.1585.

  • 4.

    Launey Y, Nesseler N, Le Cousin A, Feuillet F, Garlantezec R, Malledant Y, et al. Effect of a fever control protocol-based strategy on ventilator-associated pneumonia in severely brain-injured patients. Crit Care. 2014;18(6):689. [PubMed ID: 25498970]. [PubMed Central ID: PMC4279880]. https://doi.org/10.1186/s13054-014-0689-4.

  • 5.

    Rumbus Z, Matics R, Hegyi P, Zsiboras C, Szabo I, Illes A, et al. Fever Is Associated with Reduced, Hypothermia with Increased Mortality in Septic Patients: A Meta-Analysis of Clinical Trials. PLoS One. 2017;12(1). e0170152. [PubMed ID: 28081244]. [PubMed Central ID: PMC5230786]. https://doi.org/10.1371/journal.pone.0170152.

  • 6.

    Young PJ, Bellomo R, Bernard GR, Niven DJ, Schortgen F, Saxena M, et al. Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019;45(4):468-76. [PubMed ID: 30741326]. https://doi.org/10.1007/s00134-019-05553-w.

  • 7.

    Ye S, Xu D, Zhang C, Li M, Zhang Y. Effect of Antipyretic Therapy on Mortality in Critically Ill Patients with Sepsis Receiving Mechanical Ventilation Treatment. Can Respir J. 2017;2017:3087505. [PubMed ID: 28386165]. [PubMed Central ID: PMC5366196]. https://doi.org/10.1155/2017/3087505.

  • 8.

    Schell-Chaple HM, Puntillo KA, Matthay MA, Liu KD, National Heart L, Blood Institute Acute Respiratory Distress Syndrome N. Body temperature and mortality in patients with acute respiratory distress syndrome. Am J Crit Care. 2015;24(1):15-23. [PubMed ID: 25554550]. [PubMed Central ID: PMC4464553]. https://doi.org/10.4037/ajcc2015320.

  • 9.

    Young PJ, Prescott HC. When less is more in the active management of elevated body temperature of ICU patients. Intensive Care Med. 2019;45(9):1275-8. [PubMed ID: 31218430]. [PubMed Central ID: PMC6721989]. https://doi.org/10.1007/s00134-019-05668-0.

Mahdi Movahed-Abtahi
2021-05-17 07:46:18
Temperature control in patient with covid-19 depends to three inflammatory, cytokine storm, and coagulopathy phases. Fever in the first phase is an normal immune response to viremia while fever in the second phase is an altered immune response to inflammation. Recurrence of fever in a afebrile patient in the second or third phase is a sign of re-balancing immune response. So, the goals of treatment is different in different phases: Fever suppression is preferable in the first phase (not in the second or third phase) to save quality of life of patients.